FDA criticizes ‘politically motivated’ backlash regarding SSRI health risk assessment in pregnancy
FDA Responses to Criticism Over Antidepressants in Pregnancy The U.S. Food and Drug Administration has pushed back against healthcare providers’ concerns regarding its approach to investigating the health risks associated with antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), during pregnancy. Several health organizations, including the American College of Obstetricians and Gynecologists, have taken issue with […]